Table 2 Synergistic inhibitory effects of IDPP with other HCV inhibitors.

From: A Novel Inhibitor IDPP Interferes with Entry and Egress of HCV by Targeting Glycoprotein E1 in a Genotype-Specific Manner

Drug Combination

Combination ratioa

CIb at inhibition of

Mean CI ± SDc

Descriptiond

50%

75%

90%

95%

IDPP + Telaprevir

1:0.0001

0.833

0.841

0.866

0.889

0.87 ± 0.01

Synergism

IDPP + Daclatasvir

1:2

0.769

0.581

0.485

0.404

0.50 ± 0.00

Synergism

IDPP + Sofosbuvir

1:0.0002

1.100

1.032

0.991

0.972

1.00 ± 0.04

Additive

IDPP + IFN-α

1:0.00002

0.622

0.365

0.214

0.149

0.26 ± 0.00

Synergism

  1. aCombination ratio of two drugs as depicted.
  2. bCI values were determined by isobologram equations: CI = [(D)1/(Dx)1] + [(D)2/(Dx)2], where Dx = Dm[fa/(1-fa)]1/m as described previously29.
  3. cMean CI values were determined by following formula: [CI50 + 2CI75 + 3CI90 + 4CI95]/10. Data represent the average CI value ± SD from two independent assays (n = 2).
  4. dDescription of CI values: synergism (CI ≤ 0.9), additive effect (0.9 < CI < 1.1), and antagonism (CI ≥ 1.1).
Back to article page